Paisana Eunice, Cascão Rita, Alvoeiro Magda, Félix Francisco, Martins Guilherme, Guerreiro Carla, Roque Rafael, Cruz Rafael, Pacheco Teresa R, Amado Ana Cristina, Ferro Filipa, Lopes Machado Andrea, Vilariça Ana Sofia, Hasmucrai Direndra, Alves Paula, Faria Claudia C
GIMM - Gulbenkian Institute for Molecular Medicine, Lisboa, Portugal.
Thoracic Surgery Department, Hospital Pulido Valente, Unidade Local de Saúde de Santa Maria (ULSSM), Lisboa, Portugal.
NPJ Precis Oncol. 2025 May 6;9(1):130. doi: 10.1038/s41698-025-00901-0.
Brain metastases (BM) occur frequently in lung cancer, particularly in non-small cell lung cancer (NSCLC) patients and remain a significant cause of morbidity and mortality. Standard therapies have limited efficacy due to poor crossing of the blood-brain barrier and the distinct features between BM and the primary tumor. This review explores the immune landscape of brain metastatic disease, emerging immunotherapeutic strategies, and promising biomarkers in NSCLC patients.
脑转移（BM）在肺癌中频繁发生，尤其是在非小细胞肺癌（NSCLC）患者中，并且仍然是发病和死亡的重要原因。由于血脑屏障的通透性差以及脑转移瘤与原发肿瘤之间的明显差异，标准疗法的疗效有限。本综述探讨了非小细胞肺癌患者脑转移疾病的免疫格局、新兴的免疫治疗策略以及有前景的生物标志物。
